<DOC>
	<DOCNO>NCT02636842</DOCNO>
	<brief_summary>The study determine safety , tolerability , pharmacokinetics aripiprazole lauroxil adult schizophrenia schizoaffective disorder .</brief_summary>
	<brief_title>A Study Aripiprazole Lauroxil Subjects With Schizophrenia Schizoaffective Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Aripiprazole lauroxil</mesh_term>
	<criteria>Has diagnosis chronic schizophrenia schizoaffective disorder Has demonstrate ability tolerate aripiprazole Has stable antipsychotic medication regimen without change least 2 month prior screen Has body mass index ( BMI ) 18.0 40.0 kg/m2 , inclusive Additional criterion may apply Is pregnant , plan become pregnant , currently breastfeed Has receive aripiprazole lauroxil IM depot aripiprazole within 6 month , longacting , injectable antipsychotic medication within 3 month currently treat clozapine Is danger himself/herself screen upon admission Has history positive test result human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C Has positive urine drug screen screen Day 1 Additional criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective Disorder</keyword>
	<keyword>Aripiprazole Lauroxil</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>ALKS 9072</keyword>
	<keyword>Alkermes</keyword>
</DOC>